RESUMO
Objective To investigate the safety and clinical efficacy of CT-guided radioactive ~(125)I seed implantation treatment for advanced lung cancer. Methods The clinical data of thirty cases with lung cancer, which was proved by puncture biopsy, histology or cytology, were retrospectively analyzed. The pathologic diagnoses included squamous cell carcinoma (n= 13), adenocarcinoma (n= 8) and metastatic lung cancer (n= 9). Using treatment planning system (TPS) 3D images of the tumor were reconstructed, the number and the dose rate distribution of ~(125)I seeds were calculated. The matched peripheral dose (MPD) of ~(125)I seed implantation was 80-130 Gy. The median amount of implanted ~(125)I seeds was 35 (8-83) in number. Results Follow-up observation was made at 1, 3, 6 and 12 months after the treatment in all patients. The median survival time was 12 months (7-18 months). The cumulative survival rate at 6, 9 and 12 months was 100.0%, 80.0% and 23.3%, respectively. Follow-up CT images 12 months after the therapy showed that complete relief (CR) was seen in 9 cases, partial relief (PR) in 14 cases, no change (NC) in 4 cases and progression (PD) in 3 cases. The overall effective rate (CR + PR) of 1-month, 3-month, 6-month and 12-month was 83%, 80%, 80% and 77%, respectively. During following-up period, pneumothorax occurred in 3 cases and bloody sputum occurred in 7 cases. Conclusion CT-guided radioactive ~(125)I seed implantation treatment is a safe, effective and minimally-invasive treatment for lung cancer.